Show simple item record

dc.contributor.authorKingston, S
dc.contributor.authorMurphy, B P
dc.date.accessioned2011-03-21T12:23:19Z
dc.date.available2011-03-21T12:23:19Z
dc.date.issued2010-05
dc.identifier.citationPalivizumab use in preterm neonates. 2010, 103 (5):141-4 Ir Med Jen
dc.identifier.issn0332-3102
dc.identifier.pmid20666085
dc.identifier.urihttp://hdl.handle.net/10147/125153
dc.description.abstractRespiratory syncytial virus (RSV) is the leading cause of bronchiolitis in infants. Palivizumab is an immunoprophylactic agent for RSV prevention in preterm infants and those with neonatal chronic lung disease. This study examines its use across neonatal units in Ireland. A questionnaire was administered to one Consultant Neonatologist or Paediatrician in each of the 20 maternity centres in Ireland about their guidelines for Palivizumab administration. There is variation in administration of Palivizumab with little consistency found between protocols reported in terms of age and presence of chronic lung disease. Ten centres have in house protocols, 3 centres use the American Academy of Paediatrics (AAP) guidelines, 2 centres prefer the UK Joint Committee on Vaccination and Immunisation (JCVI) guidelines and 3 centres do not have a set protocol. Four participants felt its use has impacted on hospital admissions and 61% believe its use is cost effective. The budgetary implication for immunoprophylaxis with Palivizumab in Ireland is estimated at 1.5 to 2 million euros annually. Given current pharmacoeconomic constraints there is a need to implement a national protocol on RSV immunoprophylaxis.
dc.language.isoenen
dc.subject.meshAntibodies, Monoclonal
dc.subject.meshAntiviral Agents
dc.subject.meshBronchiolitis
dc.subject.meshClinical Protocols
dc.subject.meshFemale
dc.subject.meshGuideline Adherence
dc.subject.meshHumans
dc.subject.meshInfant, Newborn
dc.subject.meshInfant, Premature
dc.subject.meshIreland
dc.subject.meshMale
dc.subject.meshPhysician's Practice Patterns
dc.subject.meshQuestionnaires
dc.subject.meshRespiratory Syncytial Virus Infections
dc.titlePalivizumab use in preterm neonates.en
dc.typeArticleen
dc.contributor.departmentDepartment of Neonatology, Cork University Maternity Hospital, Wilton, Cork.en
dc.identifier.journalIrish medical journalen
refterms.dateFOA2018-08-22T11:33:46Z
html.description.abstractRespiratory syncytial virus (RSV) is the leading cause of bronchiolitis in infants. Palivizumab is an immunoprophylactic agent for RSV prevention in preterm infants and those with neonatal chronic lung disease. This study examines its use across neonatal units in Ireland. A questionnaire was administered to one Consultant Neonatologist or Paediatrician in each of the 20 maternity centres in Ireland about their guidelines for Palivizumab administration. There is variation in administration of Palivizumab with little consistency found between protocols reported in terms of age and presence of chronic lung disease. Ten centres have in house protocols, 3 centres use the American Academy of Paediatrics (AAP) guidelines, 2 centres prefer the UK Joint Committee on Vaccination and Immunisation (JCVI) guidelines and 3 centres do not have a set protocol. Four participants felt its use has impacted on hospital admissions and 61% believe its use is cost effective. The budgetary implication for immunoprophylaxis with Palivizumab in Ireland is estimated at 1.5 to 2 million euros annually. Given current pharmacoeconomic constraints there is a need to implement a national protocol on RSV immunoprophylaxis.


Files in this item

Thumbnail
Name:
Article5449.pdf
Size:
10.74Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record